You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 開拓藥業升超16%,進行普克魯胺治療新型冠狀病毒肺炎的研究
uSMART友信智投 07-13 11:42

uSMART友信智投7月13日消息,週一港股,開拓藥業-B高開高走,截至10:20分,開拓藥業-B升16.16%,報16.68港元。

消息面上,開拓藥業7月12日公佈,於2020年7月7日,蘇州開拓藥業股份有限公司(公司全資附屬公司)與Applied Biology,Inc.訂立臨床試驗研究協議,據此,蘇州開拓聘請Applied Biology進行普克魯胺(GT0918)治療新型冠狀病毒肺炎的研究。

Applied Biology,一家於2002年依據美國加州法律成立的公司,為一家專營治療雄激素及毛髮疾病突破性藥物及器械研發的生技公司。

普克魯胺(GT0918)為開拓藥業集團的主要在研藥物,正在中國進行轉移去勢抵抗性前列腺癌的III期臨床試驗,計劃於2020年提交新藥申請。

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account